Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA
Key Highlights
- ➤FDA agrees to pool safety data from four Alzheimer’s and Parkinson’s studies
- ➤NDA submission planned after DUET-AD data readout
- ➤Pooled studies expected to include over 1,600 buntanetap-treated participants by DUET-AD’s six-month readout
- ➤FDA recommendations will guide integrated analysis and updated Study Data Standardization Plan
- ➤FDA agreement does not ensure buntanetap NDA acceptance or approval
Expert Statements
Maria Maccecchini, President, Founder and CEO of Annovis Bio
“An NDA has to show not only that a drug works, but that it is safe in a large population treated over a long period”
Maria Maccecchini, President, Founder and CEO of Annovis Bio
“Because buntanetap acts through the same mechanism in Alzheimer’s and Parkinson’s diseases, FDA’s agreement on pooling and presentation allows us to bring the safety data from both programs together into a single, extensive database.”
Maria Maccecchini, President, Founder and CEO of Annovis Bio
“It also means we can build the safety package now, while DUET-AD and OLE PD are still ongoing.”
* FDA agrees with plan to pool safety data from four Alzheimer’s and Parkinson’s studies and to integrate it at the level of standardized analysis datasets * Safety package will be built in parallel with ongoing studies; NDA submission planned after DUET-AD data readout MALVERN, Pa., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has agreed to the Company’s Integrated Summary of Safety (ISS) plan, including a proposed strategy to pool safety data from its AD and PD clinical studies and to integrate the pooled data at the level of standardized analysis datasets, in support of its planned New Drug Application (NDA) for buntanetap.
Get started
Create a free account to read the full story.
